Telix Pharmaceuticals (TLX) Accounts Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Accounts Payables for 3 consecutive years, with $150.3 million the latest figure, recorded in Q4 2025.

• Quarterly Accounts Payables rose 209.89% year-over-year to $150.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $150.3 million (up 209.89% YoY) and the FY2025 annual result came in at $150.3 million, up 73.23% from the prior year.
• Accounts Payables grew to $150.3 million in Q4 2025 per TLX's latest filing, from $48.5 million in the prior quarter.
• Over the last five years, Accounts Payables for TLX reached as high as $150.3 million in Q4 2025 and fell as low as $48.5 million in Q4 2024.
• A 3-year average of $85.5 million and a median of $57.7 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables slipped 15.92% — and 2025, when it jumped 209.89%.
• Year by year, Accounts Payables stood at $57.7 million in 2023, then slipped by 15.92% to $48.5 million in 2024, then soared by 209.89% to $150.3 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $150.3 million, $48.5 million, and $57.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.